Table 4.
Relative risks and 95% confidence intervals associated with duration and recency of estrogen plus progestin use
| Age-adjusted | Multivariate- adjusted * |
|||
|---|---|---|---|---|
| No. Cases |
RR (95% CI) | RR (95% CI) | ||
| Never Use | 393 | 1.0 (reference) | 1.0 (reference) | |
| Duration (years) |
<2 | 48 | 0.79 (0.58-1.07) | 0.83 (0.60-1.15) |
| 2-5 | 18 | 0.46 (0.29-0.74) | 0.52 (0.32-0.87) | |
| >5 | 19 | 0.92 (0.58-1.47) | 1.12 (0.67-1.82) | |
| Recency † (years ago) |
Current | 32 | 0.78 (0.54-1.13) | 0.99 (0.67-1.47) |
| <5 | 14 | 0.58 (0.34-0.99) | 0.60 (0.34-1.05) | |
| ≥5 | 14 | 0.56 (0.32-0.95) | 0.55 (0.32-0.98) | |
*
Adjusted for age, calendar time, NSAID use, cigarette smoking, family history of colorectal cancer, percent calories from fat, and red meat intake.
†
Unknown recency of use accounted for 25 cancers and 21,984 person-years.